Key facts
- Rythm Health’s last known valuation is $73.3M (Nov 2025).
- It has raised $24.8M across 3 recorded rounds; the latest was Early Stage VC ($31.1M) in Jun 2026.
- Notable investors include Collaborative Fund, Courtside Ventures, Flying Fox Ventures, Referent Ventures, DML Group — 9 tracked in total.
- Rythm Health has filed 4 Form Ds with the SEC since 2025, most recently Jun 2026 ($31.1M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Rythm Health
Funding rounds
3 roundsAbout Rythm Health
Developer of blood testing kits intended to track health performance. The company provides kits and biomarkers for at-home testing to check cardio and endurance, muscle and cell health, recovery and resilience progress, thyroid and anemia assessment, and omega checks, enabling users to keep track of what is happening in the body and make improvements according to the results.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 7
- Website
- rythmhealth.com/
- Ownership
- Privately Held (backing)
Rythm Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rythm Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rythm Health in its N-PORT filings yet. We sweep new filings monthly.